Samsung Bioepis Co., Ltd.: HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2
Recall reason: Lack of Assurance of Sterility.. Recalled by Samsung Bioepis Co., Ltd.. Distribution: Distributed only to one warehouse in NJ. with no further distribution. Classification (Class II — potential health risk). Affected lots/NDC/dates: Lot: F2505017, Expiry: 24-Jan-2027. Return the recalled medication to the pharmacy where you purchased it for a full refund of the purchase price.
📬 Get email alerts for new Product Recalls & Refunds
Free — we'll email you when new matching opportunities appear. No spam, unsubscribe anytime.
New here? Here's how Reward Opportunity works:
🔔 More Product Recalls & Refunds
Product recalls offering refunds, replacements, or repairs to consumers who purchased the item.
Browse all product recalls & refunds →Not just this one — find everything you qualify for
Our AI scans 8,000+ bounties, settlements, grants, recalls, and paid studies against your profile to rank what you can actually claim.
Get My Free Match Report